Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Inhibition of NR4A1 Promotes Ros Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma.

Hedrick E, Mohankumar K, Lacey A, Safe S.

Mol Cancer Res. 2019 Aug 28. doi: 10.1158/1541-7786.MCR-19-0408. [Epub ahead of print]

PMID:
31462501
2.

The foot and ankle structures reveal emergent properties analogous to passive springs during human walking.

Hedrick EA, Stanhope SJ, Takahashi KZ.

PLoS One. 2019 Jun 7;14(6):e0218047. doi: 10.1371/journal.pone.0218047. eCollection 2019.

3.

Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.

Hedrick E, Li X, Cheng Y, Lacey A, Mohankumar K, Zarei M, Safe S.

Breast Cancer Res Treat. 2019 Aug;177(1):29-40. doi: 10.1007/s10549-019-05279-9. Epub 2019 May 22.

PMID:
31119568
4.

Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma.

Lacey A, Hedrick E, Cheng Y, Mohankumar K, Warren M, Safe S.

Mol Cancer Ther. 2018 Dec;17(12):2756-2766. doi: 10.1158/1535-7163.MCT-18-0118. Epub 2018 Sep 6.

PMID:
30190424
5.

TGFβ-Induced Lung Cancer Cell Migration Is NR4A1-Dependent.

Hedrick E, Mohankumar K, Safe S.

Mol Cancer Res. 2018 Dec;16(12):1991-2002. doi: 10.1158/1541-7786.MCR-18-0366. Epub 2018 Aug 2.

PMID:
30072581
6.

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR, Waters NJ, Suttle AB, Clawson A, Pollock R, Krivtsov A, Armstrong SA, DiMartino J, Hedrick E, Löwenberg B, Tallman MS.

Blood. 2018 Jun 14;131(24):2661-2669. doi: 10.1182/blood-2017-12-818948. Epub 2018 May 3.

7.

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V.

Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9.

PMID:
29650362
8.

Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development.

Safe S, Abbruzzese J, Abdelrahim M, Hedrick E.

Cancer Prev Res (Phila). 2018 Jul;11(7):371-382. doi: 10.1158/1940-6207.CAPR-17-0407. Epub 2018 Mar 15. Review.

9.

Role of metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) in pancreatic cancer.

Cheng Y, Imanirad P, Jutooru I, Hedrick E, Jin UH, Rodrigues Hoffman A, Leal de Araujo J, Morpurgo B, Golovko A, Safe S.

PLoS One. 2018 Feb 1;13(2):e0192264. doi: 10.1371/journal.pone.0192264. eCollection 2018.

10.

Correction for Hedrick et al., "NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration".

Hedrick E, Lee SO, Doddapaneni R, Singh M, Safe S.

Mol Cell Biol. 2017 Aug 28;37(18). pii: e00197-17. doi: 10.1128/MCB.00197-17. Print 2017 Sep 15. No abstract available.

11.
12.

Piperlongumine Induces Reactive Oxygen Species (ROS)-Dependent Downregulation of Specificity Protein Transcription Factors.

Karki K, Hedrick E, Kasiappan R, Jin UH, Safe S.

Cancer Prev Res (Phila). 2017 Aug;10(8):467-477. doi: 10.1158/1940-6207.CAPR-17-0053. Epub 2017 Jul 3.

13.

The nuclear orphan receptor NR4A1 regulates β1-integrin expression in pancreatic and colon cancer cells and can be targeted by NR4A1 antagonists.

Hedrick E, Lee SO, Safe S.

Mol Carcinog. 2017 Sep;56(9):2066-2075. doi: 10.1002/mc.22662. Epub 2017 May 9.

14.

Benzyl Isothiocyanate (BITC) Induces Reactive Oxygen Species-dependent Repression of STAT3 Protein by Down-regulation of Specificity Proteins in Pancreatic Cancer.

Kasiappan R, Jutooru I, Karki K, Hedrick E, Safe S.

J Biol Chem. 2016 Dec 30;291(53):27122-27133. doi: 10.1074/jbc.M116.746339. Epub 2016 Nov 15.

15.

Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors.

Hedrick E, Li X, Safe S.

Mol Cancer Ther. 2017 Jan;16(1):205-216. doi: 10.1158/1535-7163.MCT-16-0451. Epub 2016 Nov 3.

16.

Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS).

Lacey A, Hedrick E, Li X, Patel K, Doddapaneni R, Singh M, Safe S.

Oncotarget. 2016 May 24;7(21):31257-69. doi: 10.18632/oncotarget.9112.

17.

Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cells.

Hedrick E, Cheng Y, Jin UH, Kim K, Safe S.

Oncotarget. 2016 Apr 19;7(16):22245-56. doi: 10.18632/oncotarget.7925.

18.

NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration.

Hedrick E, Lee SO, Doddapaneni R, Singh M, Safe S.

Mol Cell Biol. 2016 Apr 15;36(9):1383-94. doi: 10.1128/MCB.00912-15. Print 2016 May. Erratum in: Mol Cell Biol. 2017 Aug 28;37(18):.

19.

Functional mismatch in a bumble bee pollination mutualism under climate change.

Miller-Struttmann NE, Geib JC, Franklin JD, Kevan PG, Holdo RM, Ebert-May D, Lynn AM, Kettenbach JA, Hedrick E, Galen C.

Science. 2015 Sep 25;349(6255):1541-4. doi: 10.1126/science.aab0868. Epub 2015 Sep 24.

PMID:
26404836
20.

Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC.

Gandhy SU, Imanirad P, Jin UH, Nair V, Hedrick E, Cheng Y, Corton JC, Kim K, Safe S.

Oncotarget. 2015 Sep 22;6(28):26359-72. doi: 10.18632/oncotarget.4560.

21.

Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.

Hedrick E, Lee SO, Doddapaneni R, Singh M, Safe S.

Endocr Relat Cancer. 2015 Oct;22(5):831-40. doi: 10.1530/ERC-15-0063. Epub 2015 Jul 30.

PMID:
26229035
22.

Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.

Hedrick E, Crose L, Linardic CM, Safe S.

Mol Cancer Ther. 2015 Sep;14(9):2143-53. doi: 10.1158/1535-7163.MCT-15-0148. Epub 2015 Jul 10.

23.

Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma.

Hedrick E, Lee SO, Kim G, Abdelrahim M, Jin UH, Safe S, Abudayyeh A.

PLoS One. 2015 Jun 2;10(6):e0128308. doi: 10.1371/journal.pone.0128308. eCollection 2015.

24.

Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells.

Lee SO, Li X, Hedrick E, Jin UH, Tjalkens RB, Backos DS, Li L, Zhang Y, Wu Q, Safe S.

Mol Endocrinol. 2014 Oct;28(10):1729-39. doi: 10.1210/me.2014-1102. Epub 2014 Aug 6.

25.

Analysis of environmental contamination resulting from catastrophic incidents: part 1. Building and sustaining capacity in laboratory networks.

Magnuson M, Ernst H, Griggs J, Fitz-James S, Mapp L, Mullins M, Nichols T, Shah S, Smith T, Hedrick E.

Environ Int. 2014 Nov;72:83-9. doi: 10.1016/j.envint.2014.01.015. Epub 2014 Feb 15.

PMID:
24534702
26.

Comparison of nucleic acid extraction and reverse transcription-qPCR approaches for detection of GI and GII noroviruses in drinking water.

Griffin SM, Brinkman NE, Hedrick EJ, Rhodes ER, Fout GS.

J Virol Methods. 2014 Apr;199:76-85. doi: 10.1016/j.jviromet.2014.01.005. Epub 2014 Jan 22.

PMID:
24462844
27.

Minireview: role of orphan nuclear receptors in cancer and potential as drug targets.

Safe S, Jin UH, Hedrick E, Reeder A, Lee SO.

Mol Endocrinol. 2014 Feb;28(2):157-72. doi: 10.1210/me.2013-1291. Epub 2013 Dec 2. Review.

28.

Differential PKA activation and AKAP association determines cell fate in cancer cells.

Hedrick ED, Agarwal E, Leiphrakpam PD, Haferbier KL, Brattain MG, Chowdhury S.

J Mol Signal. 2013 Oct 1;8(1):10. doi: 10.1186/1750-2187-8-10.

29.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S.

N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.

30.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH.

J Clin Oncol. 2013 Jan 1;31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Epub 2012 Oct 8.

31.

Real-time evidence for EF-G-induced dynamics of helix 44 in 16S rRNA.

Tanner DR, Hedrick EG, Hill WE.

J Mol Biol. 2012 Sep 7;422(1):45-57. doi: 10.1016/j.jmb.2012.05.012. Epub 2012 May 23.

32.

The formation of a potential spring in the ribosome.

Hedrick EG, Tanner DR, Baig A, Hill WE.

J Mol Biol. 2012 Feb 3;415(5):833-42. doi: 10.1016/j.jmb.2011.12.003. Epub 2011 Dec 9.

PMID:
22178475
33.

Protein S20 binds two 16S rRNA sites as assembly is initiated.

Hedrick EG, Hill WE.

J Mol Biol. 2010 Aug 20;401(3):493-502. doi: 10.1016/j.jmb.2010.06.047. Epub 2010 Jun 30.

PMID:
20600110
34.

Romancing the salve: Sir Kenelm Digby and the powder of sympathy.

Hedrick E.

Br J Hist Sci. 2008 Jun;41(149 Pt 2):161-85.

PMID:
19048798
35.

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).

Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M.

J Clin Oncol. 2008 Nov 20;26(33):5326-34. doi: 10.1200/JCO.2008.16.3212. Epub 2008 Oct 14.

PMID:
18854571
36.

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E.

J Clin Oncol. 2008 Jul 20;26(21):3523-9. doi: 10.1200/JCO.2007.15.4138. Erratum in: J Clin Oncol. 2008 Oct 1;26(28): 4697.

PMID:
18640933
37.

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ.

J Clin Oncol. 2008 Jan 10;26(2):183-9. doi: 10.1200/JCO.2007.13.8099.

PMID:
18182660
38.

Statistical procedures for determination and verification of minimum reporting levels for drinking water methods.

Winslow SD, Pepich BV, Martin JJ, Hallberg GR, Munch DJ, Frebis CP, Hedrick EJ, Krop RA.

Environ Sci Technol. 2006 Jan 1;40(1):281-8.

PMID:
16433362
40.

A mechanistic model for mercury capture with in situ-generated titania particles: role of water vapor.

Rodríguez S, Almquist C, Lee TG, Furuuchi M, Hedrick E, Biswas P.

J Air Waste Manag Assoc. 2004 Feb;54(2):149-56.

PMID:
14977316
41.

Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.

Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A.

Cancer. 2003 Sep 15;98(6):1196-205.

42.

Hg reactions in the presence of chlorine species: homogeneous gas phase and heterogeneous gas-solid phase.

Lee TG, Hedrick E, Biswas P.

J Air Waste Manag Assoc. 2002 Nov;52(11):1316-23.

PMID:
12469718
43.

Rituximab: ongoing and future clinical development.

Grillo-López AJ, Hedrick E, Rashford M, Benyunes M.

Semin Oncol. 2002 Feb;29(1 Suppl 2):105-12. Review.

PMID:
11842397
44.

Rituximab: Ongoing and future clinical development.

Grillo-López AJ, Hedrick E, Rashford M, Benyunes M.

Semin Oncol. 2002 Feb;29(1S2):105-112. doi: 10.1053/sonc.2002.30145.

PMID:
28140083
46.

Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A.

Leuk Lymphoma. 2001 Sep-Oct;42(5):1015-22.

PMID:
11697618
47.

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O'Brien JP, Straus D, Portlock CS, Yahalom J.

Blood. 2001 Feb 1;97(3):616-23.

48.

High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.

Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, Qin J, Lyons NC, Yahalom J, Nimer SD, Moskowitz CH.

Blood. 2000 Oct 1;96(7):2399-404.

49.

Characterization of activated carbon fiber filters for pressure drop, submicrometer particulate collection, and mercury capture.

Hayashi T, Lee TG, Hazelwood M, Hedrick E, Biswas P.

J Air Waste Manag Assoc. 2000 Jun;50(6):922-9.

PMID:
10902384
50.

"Where's the science"?

Hedrick E.

Am J Infect Control. 2000 Feb;28(1):66-7. Review. No abstract available.

PMID:
10679140

Supplemental Content

Loading ...
Support Center